Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Missed Phase II Velafermin Endpoint Drops CuraGen

Dec. 14, 2005

By Aaron Lorenzo

Missed Phase II Velafermin Endpoint Drops CuraGen

Dec. 14, 2005

By Aaron Lorenzo

Myogen Riding High After Preliminary PAH Findings

Dec. 13, 2005

By Aaron Lorenzo

Positive Phase III news sent Myogen Inc.'s stock soaring 40.5 percent, with top-line data demonstrating ambrisentan's ability to improve symptoms of pulmonary arterial hypertension. (BioWorld Today)

Myogen Riding High After Preliminary PAH Findings

Dec. 13, 2005

By Aaron Lorenzo

Positive Phase III news sent Myogen Inc.'s stock soaring 40.5 percent, with top-line data demonstrating ambrisentan's ability to improve symptoms of pulmonary arterial hypertension. (BioWorld Today)

Gene Therapy Firm Celladon Secures $30M Commitment

Dec. 8, 2005

By Aaron Lorenzo

Gene Therapy Firm Celladon Secures $30M Commitment

Dec. 8, 2005

By Aaron Lorenzo

Cell Therapeutics Moves Ahead With Women-Only Cancer Study

Dec. 7, 2005

By Aaron Lorenzo

Cell Therapeutics Moves Ahead With Women-Only Cancer Study

Dec. 7, 2005

By Aaron Lorenzo

As Feds Engage States, Cel-Sci Shares Jump On Bird Flu Deal

Dec. 6, 2005

By Aaron Lorenzo

As Feds Engage States, Cel-Sci Shares Jump On Bird Flu Deal

Dec. 6, 2005

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 4, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...